Financial Performance (Standalone)

  • Revenue: ₹535 crores for Q1 FY27, representing a 42% year-on-year increase from ₹375 crores in Q1 FY26.
  • EBITDA: ₹133 crores for Q1 FY27, representing a 40% year-on-year increase from ₹95 crores in Q1 FY26.
  • Profit After Tax (PAT): ₹71 crores for Q1 FY27, representing a 49% year-on-year increase from ₹48 crores in Q1 FY26.
  • EBITDA Margin: 25.4% for Q1 FY27.
  • Gross Margin: Approximately 50% company-level guidance for sustainable levels.

Business Segment Performance

Xanthine Derivatives (57% of turnover)

  • Achieved highest-ever quarterly sales
  • Volume split: 74% beverages customers, 26% other customers
  • Geographical split: 79% exports, 21% local sales
  • Current production: ~6,000 metric tons annually
  • Capacity expansion: Enhanced to 9,500 metric tons with new brownfield site (L99)
  • Target global market share: 20-25% within next 2 years
  • Primary competition: 80-90% China-based producers

API and Intermediates (30% of turnover)

  • Market split: 58% regulated market, 14% rest of world, 28% non-regulated market
  • Facing pricing pressures in existing molecules
  • Process intensification and cost reduction initiatives underway
  • Top 10 products contribute 60-70% of segment revenue
  • Market share in top products: Between 10-50%

CDMO/CMO Services (7% of turnover)

  • Working with 22 customers
  • 57 active projects: 37 commercial stage, 20 developmental stage
  • Revenue pattern: Skewed toward second half of financial year
  • Growth guidance: 40-50% for FY27
  • Target: ₹1,000 crores CDMO revenue
  • Gross margins: ~60-65% on commercial side

Others (6% of turnover)

  • Includes trading sales, export incentives, scrap sales, and group buying (solvents)
  • Not significantly revenue or gross margin accretive

Capacity Expansion and Capex Update

Completed Projects (Q1 FY27)

  • Tarapur Unit 4 (USFDA approved API site): Debottlenecking of steroid block completed, adding 33% additional steroidal capacity
  • Xanthine derivatives: Additional capacity commercialized with trial production ongoing

Ongoing Projects

  • Atali Block 1: 440 kL reactor capacity, both phases to become fully operational in Q2 FY27
  • Majorly engaged in manufacturing CDMO/CMO intermediate steps

New Announcement

  • Atali Block 2: ₹149 crores capex for 400+ kL reactor capacity
  • Groundbreaking expected in Q3 FY27
  • Completion timeline: 12-15 months
  • Dedicated to specific CDMO projects, more cost-effective than multipurpose blocks
  • Additional 200 kL flexibility possible with short notice

Operational Guidance and Outlook

  • Xanthine business: Targeting 80%+ capacity utilization by FY28
  • Xanthine revenue range: ₹900-1,100 crores for FY27
  • EBITDA margin guidance: 22-25% for full year FY27
  • CDMO/CMO: Expected to contribute 20% of overall revenue eventually
  • R&D expenditure: ~7% of API intermediates and CDMO revenue, with more than 50% allocated to CDMO

Management Commentary

  • Raw material impact: West Asia crisis caused raw material prices to increase 50-100%, which have since moderated to 25-50% above normal levels
  • Price pass-through: Xanthine business has raw material pass-through mechanisms with large customers
  • China impact: Anti-involution policy removed rebates, structurally increasing Xanthine prices
  • Capacity ramp-up: Additional Xanthine capacity will mitigate realization declines through increased volumes
  • CDMO strategy: Moving mature projects to dedicated blocks while keeping multipurpose blocks free for newer projects

Subsidiary Update

  • Ganesh Polychem: Strong quarter with ₹7 crores PAT after rationalizing ₹2.5 crores dividend income

Conference Call Participants

  • Management: Mr. Rashesh Gogri (Chairman), Mr. Piyush Lakhani (CFO)
  • Moderator: Ms. Julie Mehta (360 ONE Capital Markets Private Limited)
  • Analysts: Representatives from Vyomara Capital, Niveshaay Asset Management, Unifi Capital, Bamboo Capital, Avener Investment Management, Credence Wealth, Antifragile Thinking, Boring AMC, Burman Capital, Padmaja Investments, Lucky, ICICI Securities, Leo Capital, Turtle Capital